The Effect of Dual Antiplatelet Post Percutaneous Coronary Intervention On Aggregation of Platelet In Myocardial Infarction Patients With Diabetes Mellitus and Non Diabetes Mellitus

To analyze the differences in the effect of dual antiplatelet post PCI on the percentage of aggregation in myocardial infarction patients with DM and non DM. Percentage of aggregation were analyzed using light transmission aggregometry (LTA) before loading dose, after PCI, and after maintenance dose of dual antiplatelet (aspirin 100mg and clopidogrel 75mg). Total 22 patients were participated in this study divided into 10 and 12 patients in diabetic and non diabetic group. Percentage of aggregation after taking dual antiplatelet maintenace dose decrease significantly in both group (p=0.006 in diabetic group and p=0.002 in non diabetic group). Mean reduction of percentage of aggregation in diabetic group (3.30±2.91%) is less than non diabetic group (6.83±5.97%). Statistical analysis shows that the mean reduction of percentage of aggregation between two groups were not significantly different (p>0.05). Mean percentage of aggregation after dual antiplatelet maintenance dose was higher in diabetic group and mean reduction of percentage of aggregation was higher in non diabetic group, although statistically in both group it is not significantly different

Efektivitas Deferasirox pada Pasien Thalasemia Mayor: Artikel Review: Efficacy of Deferasirox for Thalassemia Mayor: Review Article

Thalassemia is a heterogeneous grouping of genetic disorders resulting from decreased synthesis of the alpha or beta chains of hemoglobin. Anemia and iron overload are the main causes of morbidity and mortality due to thalassemia disease. Iron chelation has improved the survival and quality of life of patients with thalassemia major. Deferasirox (DFX) was developed as monotherapy for the treatment of transfusion iron overload. Search data in this literature study using an electronic database, namely Science Direct, Pubmed with the keywords thalassemia, deferasirox and efficacy. The search results obtained 1015 articles and 5 articles that matched the inclusion and exclusion criteria. The total patients in this study were 410 people from 5 countries. The results of the review article found that deferasirox was effective in reducing iron in the body as seen from the LIC (Liver Iron Concentration), T2* heart and serum ferritin in patients with thalassemia major